Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Gemcitabine and Paclitaxel in Advanced NSCLC and Solid Tumors
NCT00004159Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Feb 2000
- Primary completion
- Feb 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by University of Alabama at Birmingham. Primary endpoints: Maximum Tolerated Dose and Dose Limiting Toxicities. Started Feb 2000; status: terminated.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT00004159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004159.